Irifrin - pata kanohi

"Irifrin" - makaka kanohi, he mārama, taekore otinga kōwhai marama ranei ratou. Tenei faaineineraa kua he mahi alpha-adrenergic korerotia. "Irifrin" pata kanohi i kahore pānga kitea whakaongaonga i runga i te pūnaha io pokapū. tono ana tēnei waihanga te topically, ai reira pū o te tauira, he matamua ake me intraocular inu vasoconstriction kirikamo.

"Irifrin" - tohutohu mō te whakamahi

I te ngakau o tenei tarukino ko phenylephrine, e whakaihiihi ana te receptors alpha-adrenergic postsynaptic me he iti mahi i runga i receptors beta-adrenergic o te ngakau. "Irifrin" eyedrops i pānga vasoconstrictor i te mea rite ki te mahi o te norepinephrine. I muri i te tarukino puta mydriasis. nohanga tihi o te phenylephrine i muri i 10-20 meneti puta i roto i te kiko kanohi

e tūtohu ana ki te whakamahi i "Irifrin" makaka kanohi i roto i nga wā e whai ake nei:

- i iridocyclitis, ki te whakaiti i exudation i te rohe o te iris, me te mo te ārai o te posterior synechiae;

- ki te kawe i roto i te roha o te tauira, te wahi e tika ana, tona tātaritanga, ki e taea ki te aroturuki i te āhua o te hoki o te kanohi;

- ki te whakatinana i te whakamātautau whakaputa mo te hunga tūroro e whai i te kōtaha kuiti o koki ruma mārōrō papahewa katinga whakapae ranei;

- mo te tātaritanga pārōnaki o werohia hohonu, me te ausia o te 'Afio ;

- ki te whakawhānui i te tauira i roto i te whakangungu predopretsionnoy;

- i roto i te pokanga vitreoretinal, i roto i te tikanga ki te whakapiki ake i te tauira, me ka mahi ana i te mahi ki te taiaho i te fundus kanohi ;

- whakahaere matatini hauora i roto i te aroaro o mōrearea papahewa-tsikliticheskih;

- i roto i te faaiteraa o te spasm o noho;

- mo te maimoatanga o pera-ka karanga syndrome o "mata whero", me te whakamahi o tenei tarukino āwhina whakaiti i kārangirangi me te kanohi kiriuhi Makere.

"Irifrin" pata kanohi - contraindications

e kore e whakamahi tēnei faaineineraa, ki te whai i te manawanui mate:

- aroaro o tauhohe mate pāwera ki te wāhanga ngā i roto i te tarukino nei hauora;

- te aroaro o te manawanui-katinga kuiti-koki papahewa ranei;

- te whakamahi o te tarukino kore e tūtohutia hoki te iwi ruhiruhia e whai raruraru nui i roto i te pūnaha Cardiovascular te pūnaha iaia roro ranei;

- e kore koe e taea e te tono i te tarukino hoki atu pū tauira i roto i te pokanga i roto i te hunga tūroro e whai he takahi o te tapatahi o te 'Afio ranei production roimata waimaero;

- contraindicated tono o te 10% otinga o mea waihanga mō ngā tamariki i raro i te 12 tau e whai aneurysm matua;

- rāhuitia te whakamahi o 2.5% otinga o kohungahunga preterm;

- contraindicated te whakamahi o te raau taero i roto i te aroaro o te hyperthyroidism, porphyria ate, hē congenital o te kūhuka-6-Phosphate dehydrogenase.

Ki te tūpato tino kia whakamahia hoatu te tarukino ki te iwi ki te mate huka, te iwi pakeke. Kaua e tangohia "Irifrin" tahi ki inhibitors Mao, he taea taua tono i muri i te wahi o te 21 nga ra i te rā o te whakamutunga o ratou whakauru.

Kaua e nui ake i te horopeta tūtohutia hoki te iwi e whai whara me mate o te kanohi ona konga ranei. Ano, e kore e tangohia te raau taero i roto i te wā postoperative, ranei ki te reira te heke production roimata.

dosing

Hei waihanga nui whakahaere mydriasis o tetahi te maturuturunga iho o 2.5% "Irifrin" i roto i te pūwhera conjunctival. kitea te pānga mōrahi te i muri i 15-30 meneti, me pumau hoki ki runga ki te toru haora. Ki te kia te tono tono o te otinga 2.5% iti, mō ngā tamariki e te hunga i runga i te 12 tau, me te tūroro pakeke he 10% otinga o te horopeta kotahi.